Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors

Cancer Investigation

Volumn 28, Issue 8, 2010, Pages 849-855

  Simon Tchekmedyian, N ^a   Chen, Yin Miao ^b   Saad, Fred ^c  

^a Pacific Shores Medical Group   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOTRE DAME HOSPITAL   (Canada)

Author keywords

Bone metastasis; Lung cancer; Prostate cancer; Zoledronic Acid

Indexed keywords

ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; PLACEBO;

ADULT; AGED; ARTICLE; BONE LESION; BONE METASTASIS; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; EXPLORATORY RESEARCH; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SOLID TUMOR; BONE NEOPLASMS; COMPLICATION; LUNG NEOPLASMS; NEOPLASMS; ORCHIECTOMY; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; NEOPLASMS; ORCHIECTOMY; PLACEBOS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77956635496     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.483508     Document Type: Article

References (21)

1. Coleman, R.E. Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev 2001, 27(3), 165-176.
2. Saad, F.; Lipton, A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007, 34(6 Suppl 4), S17-S23.
3. Weinfurt, K.P.; Castel, L.D.; Li, Y.; Timbie, J.W.; Glendenning, G.A.; Schulman, K.A. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004, 42(2), 164-175.
4. Weinfurt, K.P.; Li, Y.; Castel, L.D.; Saad, F.; Timbie, J.W.; Glendenning, G.A.; Schulman, K.A. The significance of skeletalrelated events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005, 16(4), 579-584.
5. Saad, F.; Lipton, A.; Cook, R.; Chen, Y.-M.; Smith, M.; Coleman, R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110(8), 1860-1867.
6. Halabi, S.; Vogelzang, N.J.; Kornblith, A.B.; Ou, S.-S.; Kantoff, P.W.; Dawson, N.A.; Small, E.J. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008, 26(15), 2544-2549.
7. Hirsh, V.; Tchekmedyian, N.S.; Rosen, L.S.; Zheng, M.; Hei, Y.-J. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004, 6(3), 170-174.
8. Rosen, L.S.; Gordon, D.; Tchekmedyian, N.S.; Yanagihara, R.; Hirsh, V.; Krzakowski, M.; Pawlicki, M.; De Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100(12), 2613-2621.
9. Rosen, L.S.; Gordon, D.; Tchekmedyian, S.; Yanagihara, R.; Hirsh, V.; Krzakowski, M.; Pawlicki, M.; de Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J.J. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21(16), 3150-3157.
10. Saad, F.; Gleason, D.M.; Murray, R.; Tchekmedyian, S.; Venner, P.; Lacombe, L.; Chin, J.L.; Vinholes, J.J.; Goas, J.A.; Chen, B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94(19), 1458-1468.
11. Saad, F.; Gleason, D.M.; Murray, R.; Tchekmedyian, S.; Venner, P.; Lacombe, L.; Chin, J.L.; Vinholes, J.J.; Goas, J.A.; Zheng, M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96(11), 879-882. (Pubitemid 38807610)
12. Kohno, N.; Aogi, K.; Minami, H.; Nakamura, S.; Asaga, T.; Iino, Y.; Watanabe, T.; Goessl, C.; Ohashi, Y.; Takashima, S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005, 23(15), 3314-3321.
13. Rosen, L.S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M.A.; Coleman, R.E.; Reitsma, D.J.; Chen, B.-L.; Seaman, J.J. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98(8), 1735-1744.
14. Aapro, M.; Abrahamsson, P.A.; Body, J.J.; Coleman, R.E.; Colomer, R.; Costa, L.; Crino, L.; Dirix, L.; Gnant, M.; Gralow, J.; Hadji, P.; Hortobagyi, G.N.; Jonat, W.; Lipton, A.; Monnier, A.; Paterson, A.H.G.; Rizzoli, R.; Saad, F.; Thurlimann, B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19(3), 420-432.
15. Smith, M.R.; Cook, R.J.; Coleman, R.; Brown, J.; Lipton, A.; Major, P.; Hei, Y.J.; Saad, F. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007, 70(2), 315-319.
16. Andersen, P.K.; Gill, R.D. Coxs regression model for counting processes: a large sample study. Ann Stat 1982, 10(4), 1100-1120.
17. Brown, J.E.; Cook, R.J.; Major, P.; Lipton, A.; Saad, F.; Smith, M.; Lee, K.-A.; Zheng, M.; Hei, Y.J.; Coleman, R.E. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97(1), 59-69.
18. Cook, R.J.; Coleman, R.; Brown, J.; Lipton, A.; Major, P.; Hei, Y.J.; Saad, F.; Smith, M.R. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006, 12(11 pt 1), 3361-3367.
19. Lipton, A.; Cook, R.; Saad, F.; Major, P.; Garnero, P.; Terpos, E.; Brown, J.E.; Coleman, R.E. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113(1), 193-201.
20. Hirsh, V.; Major, P.P.; Lipton, A.; Cook, R.J.; Langer, C.J.; Smith, M.R.; Brown, J.E.; Coleman, R.E. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008, 3(3), 228-236.
21. Novartis Pharmaceuticals. Zometa® (Zoledronic Acid) Injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.